Merck Global Health Innovation Fund

Merck Global Health Innovation Fund is the dedicated corporate venture arm of Merck and Co (MSD), one of the most established and active strategic investors in digital health and healthcare technology. The fund has a long-running thesis around digital health platforms, real-world data, healthcare IT, and the integration of technology into pharma commercialization and patient services, with notable historical investments across patient-facing apps, clinical-trial software, and value-based care infrastructure. Healthcare exposure is total; this is a pure-play healthcare CVC. AI focus is genuine and increasingly central, particularly around clinical trial optimization, real-world evidence, and patient identification, but the fund is not an AI-only investor and applies pharma-grade diligence to model claims. Stage spans Series A through growth, with check sizes plausibly ranging from USD 5M to USD 25M for initial positions and meaningful follow-on capacity through later rounds. This is the wrong door for pre-product or non-healthcare AI infrastructure plays. It is a serious fit for revenue-stage digital health, real-world data, and clinical-trial technology companies that benefit from a strategic pharma relationship and want a long-term anchor investor with deep operating networks across the pharma value chain. Entry path is a warm introduction from a portfolio CEO, a Merck commercial partner, or a co-investing crossover fund; founders should be ready to discuss specific pharma use cases and have a clear point of view on managing strategic-investor dynamics on the cap table.